Firastotug Biosimilar - Research Grade

Human

CTLA4ï؟½

5mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P09793;P16410

Blue ice

CTLA-4 is a key inhibitory checkpoint receptor that dampens early T-cell activation and is a cornerstone target of cancer immunotherapy research. This research-grade anti-CTLA-4 recombinant monoclonal antibody is an unconjugated, non-therapeutic analog of firastotug, distributed strictly for research use only (RUO). Produced under demanding in vivo conditions, the ultra-pure, low-endotoxin preparation is available in scalable milligram (mg) to gram (g) quantities to support high-throughput laboratories. It serves as a dependable reagent and control for checkpoint-blockade studies, in vitro T-cell assays, in vivo syngeneic tumor models, and biologics characterization.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks